Reduced claudin-3 gene expression was appreciated in a NEC mouse model, with the administration of VIP subsequently leading to increased claudin-3 gene expression, reduced inflammation, and reduced tight junction disruption in the intestinal epithelium [25]. The gene discussed is CLDN3; the disease is necrotizing enterocolitis.